10.02.2022 - Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on the prevention of cancer recurrence and addressing hard-to-treat tumors, will publish its financial results for the fourth quarter and full year ended December 31, 2021 .
Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on the prevention of cancer recurrence and addressing hard-to-treat tumors, will publish its financial results for the fourth
Investegate announcements from Immunicum AB, Immunicum AB: Invitation to Immunicum s Full-Year 2021 Review and Pipeline and Strategy Outlook Held as a Hybrid Event on February 17, 2022
05.01.2022 - Press Release Stockholm, Sweden, January 5, 2022 Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors .